Log in

NASDAQ:CGNT - Vision Sciences Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$3.85
0.00 (0.00 %)
(As of 04/23/2018)
Today's Range
$3.85
Now: $3.85
$3.85
50-Day Range N/A
52-Week Range
$1.55
Now: $3.85
$3.92
VolumeN/A
Average Volume183,912 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cogentix Medical, Inc, a medical device company, designs, develops, manufactures, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide. The company offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CGNT
CUSIPN/A
Phone952-426-6140

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive CGNT News and Ratings via Email

Sign-up to receive the latest news and ratings for CGNT and its competitors with MarketBeat's FREE daily newsletter.


Vision Sciences (NASDAQ:CGNT) Frequently Asked Questions

What is Vision Sciences' stock symbol?

Vision Sciences trades on the NASDAQ under the ticker symbol "CGNT."

How were Vision Sciences' earnings last quarter?

Vision Sciences Inc. (NASDAQ:CGNT) issued its earnings results on Tuesday, November, 3rd. The medical device company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The medical device company earned $11.80 million during the quarter, compared to analyst estimates of $11.45 million. View Vision Sciences' Earnings History.

Has Vision Sciences been receiving favorable news coverage?

Media stories about CGNT stock have trended somewhat positive this week, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vision Sciences earned a news impact score of 1.3 on InfoTrie's scale. They also gave press coverage about the medical device company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. View News Stories for Vision Sciences.

Who are some of Vision Sciences' key competitors?

What other stocks do shareholders of Vision Sciences own?

Who are Vision Sciences' key executives?

Vision Sciences' management team includes the folowing people:
  • Mr. Darin Hammers, Pres, CEO & Director (Age 53)
  • Mr. Brett A. Reynolds, Sr. VP, CFO & Corp. Sec. (Age 49)
  • Mr. Chris Arnold, VP of Global Sales (Age 50)
  • Mr. Larry Heinemann, VP of Corp. Devel. (Age 66)
  • Mr. Ash Keswani, Sr. VP of Marketing & Bus. Devel.

What is Vision Sciences' stock price today?

One share of CGNT stock can currently be purchased for approximately $3.85.

What is Vision Sciences' official website?

The official website for Vision Sciences is http://www.cogentixmedical.com/.

How can I contact Vision Sciences?

Vision Sciences' mailing address is 5420 FELTL ROAD, MINNETONKA MN, 55343. The medical device company can be reached via phone at 952-426-6140 or via email at [email protected]


MarketBeat Community Rating for Vision Sciences (NASDAQ CGNT)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  231 (Vote Underperform)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about Vision Sciences and other stocks. Vote "Outperform" if you believe CGNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel